Estée Lauder Companies
EL
$98.22
+1.13%
The Estée Lauder Companies Inc. is a global leader in the prestige beauty market, operating across skin care (49% of fiscal 2025 sales), makeup (29%), fragrance (17%), and hair care and others (5%), with a portfolio of iconic brands including Estée Lauder, Clinique, M.A.C, La Mer, Jo Malone London, Aveda, Bobbi Brown, and Origins. The company sells through department stores, travel retail, specialty multibrand beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries across more than 150 countries, generating 31% of revenue from the Americas, 37% from Europe, the Middle East and Africa (including travel retail), and 32% from Asia-Pacific. As a bellwether in the Consumer Defensive sector, Estée Lauder is distinct for its multi-brand, multi-channel platform and its heavy exposure to travel retail and Asian markets, which have been both a growth engine and a source of volatility. The current investor narrative centers on a turnaround story: after a prolonged period of earnings pressure and a failed merger discussion with Puig, the company is showing signs of accelerating sales and expanding margins, with recent headlines highlighting a stock jump on turnaround optimism and the decision to walk away from merger talks to pursue an independent plan. This has shifted debate from survival and restructuring toward the sustainability of margin recovery and the pace of top-line reacceleration, particularly in the critical Asia-Pacific and travel retail channels.…
EL
Estée Lauder Companies
$98.22
Related headlines
Investment Opinion: Should I buy EL Today?
We rate EL a Hold. The core thesis is that the company is in the early stages of a credible turnaround, with revenue growth of 4.56% in Q3 FY2026 and margin expansion, but the valuation already prices in a full recovery, leaving limited margin of safety. The analyst consensus is 'buy' with an average target of $107.04, implying 10.2% upside, but we believe the risk/reward is balanced given the high execution risk and the stock's 31.8% downside to the 52-week low.
The supporting evidence is mixed. On the positive side, revenue growth turned positive at 4.56% YoY, gross margin is a healthy 71.04%, and free cash flow of $1.285B covers the dividend. The forward P/E of 24.82x is not unreasonable if EPS hits $4.25, and the 10.2% upside to the average target is attractive. However, the trailing P/E of 157.9x and EV/EBITDA of 40.4x are extreme, and the net margin of 1.21% is far below the industry average. The debt-to-equity of 2.43 and current ratio of 1.22 indicate financial fragility. Compared to peers, EL's valuation is stretched, and its ROE of 4.78% is subpar.
The biggest risks that could invalidate the thesis are: (1) a slowdown in Asia-Pacific or travel retail that stalls revenue growth; (2) margin compression due to promotional activity or cost inflation; and (3) a failure to achieve the $4.25 EPS estimate, which would make the forward P/E look expensive. We would upgrade to Buy if the stock pulls back to the $80-85 range (implying a more reasonable forward P/E of ~20x) or if two consecutive quarters show accelerating revenue growth and margin expansion. We would downgrade to Sell if revenue growth turns negative or if operating margin falls below 8%. Relative to its history and peers, EL appears overvalued on trailing metrics but fairly valued on forward estimates, assuming the turnaround succeeds.
Sign up to view all
EL 12-Month Price Forecast
We have a neutral stance with medium confidence. The company is showing genuine signs of a turnaround, with revenue growth and margin expansion, but the valuation already reflects much of the optimism. The forward P/E of 24.82x is not cheap for a company with a 1.21% net margin and 4.78% ROE, and the high debt load adds risk. The analyst consensus is bullish, but the stock's recent rally may have priced in the near-term catalysts. We would upgrade to bullish if the next two quarters show accelerating revenue growth (above 5%) and operating margin above 10%, or if the stock pulls back to the $80-85 range. We would downgrade to bearish if revenue growth turns negative or if operating margin falls below 8%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Estée Lauder Companies's 12-month outlook, with a consensus price target around $107.04 and implied upside of +9.0% versus the current price.
Average Target
$107.04
0 analysts
Implied Upside
+9.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$70 - $127
Analyst target range
Drowning in data?
Find the real signal!
Bulls vs Bears: EL Investment Factors
The bull case rests on tangible evidence of a turnaround: revenue growth of 4.56% in Q3 FY2026, margin expansion, and a 10.2% upside to analyst targets. The bear case highlights the extreme valuation (157.9x trailing P/E, 40.4x EV/EBITDA), high debt (D/E 2.43), and a history of earnings volatility that makes the forward EPS estimate of $4.25 a high hurdle. Currently, the bull side has stronger near-term momentum, as reflected in the 11.83% relative strength over the past month and the stock's 16.5% jump on August 19. However, the single most important tension is whether the margin recovery can be sustained while revenue growth accelerates, particularly in the critical Asia-Pacific and travel retail channels. If the next earnings report shows continued margin expansion and top-line growth, the bull case will strengthen; if margins compress or sales decelerate, the stock could quickly retest its 52-week low.
Bullish
- Turnaround momentum confirmed by accelerating sales: Q3 FY2026 revenue of $3.712B grew 4.56% year-over-year, reversing the prior-year declines, and the stock jumped 16.5% on August 19, 2026 (from $84.27 to $98.01) on turnaround optimism. This marks a clear inflection from the negative revenue prints in FY2025, when Q2 FY2025 revenue fell to $4.004B from $4.238B in Q2 FY2026.
- Margin recovery is underway: Gross margin expanded to 71.04% in Q3 FY2026 from 74.96% in Q3 FY2025, but operating margin improved to 9.64% from 8.62% year-over-year, and net income swung to $89M from $159M. More importantly, Q2 FY2026 gross margin reached 76.55% and operating margin 13.85%, showing the potential when sales mix normalizes.
- Analyst consensus sees 10.2% upside: With 27 analysts covering the stock, the average target price is $107.04 versus the current price of $97.12, implying 10.2% upside. The high target of $127.00 suggests 30.8% upside if the turnaround exceeds expectations, and the consensus recommendation is 'buy' with a mean of 2.34.
- Strong free cash flow and dividend support: The company generated $1.285B in trailing free cash flow, which comfortably covers its dividend (1.78% yield) despite a payout ratio of 279% on trailing EPS. As earnings recover toward the forward EPS estimate of $4.25, the payout ratio should normalize, and the dividend provides a floor for valuation.
Bearish
- Extreme valuation multiples despite weak earnings: The trailing P/E is 157.9x and EV/EBITDA is 40.37x, both exceptionally high for a company with a net margin of just 1.21% and ROE of 4.78%. Even the forward P/E of 24.82x relies on EPS growing from $0.006 to $4.25, a massive jump that may not materialize if the turnaround stalls.
- High debt burden and low current ratio: Debt-to-equity stands at 2.43, and the current ratio is only 1.22, indicating limited liquidity cushion. Interest expense of $82M per quarter consumes a significant portion of operating income ($358M in Q3 FY2026), leaving little room for error if sales disappoint.
- Earnings volatility and history of losses: The company reported negative EPS in four of the last eight quarters, including -$1.51 in Q4 FY2025 and -$1.64 in Q2 FY2025. This volatility makes forecasting difficult and raises questions about the sustainability of the recent profitability.
- Underperformance versus the market over the past year: Despite recent gains, EL has underperformed the S&P 500 by 4.34 percentage points over the past year and by 21.11 percentage points year-to-date. The stock is down 9.03% YTD while the S&P 500 is up 12.08%, indicating that the broader market recovery has bypassed EL.
EL Technical Analysis
Beta
1.27
1.27x market volatility
Max Drawdown
-43.8%
Largest decline past year
52-Week Range
$66-$122
Price range past year
Annual Return
+17.4%
Cumulative gain past year
| Period | EL Return | S&P 500 |
|---|---|---|
| 1m | +14.1% | -2.0% |
| 3m | +12.1% | +1.4% |
| 6m | +14.2% | +15.0% |
| 1y | +17.4% | +15.7% |
| ytd | -8.0% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EL Fundamental Analysis
Quarterly Revenue
$3.7B
2026-03
Revenue YoY Growth
+4.6%
YoY Comparison
Gross Margin
71.0%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EL Overvalued?
PE
157.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 28x~169x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
40.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. The company carries a debt-to-equity ratio of 2.43 and a current ratio of just 1.22, leaving limited liquidity buffer. Interest expense of $82M per quarter consumes 23% of operating income, and the trailing net margin is a razor-thin 1.21%. The payout ratio of 279% on trailing EPS means the dividend is not covered by current earnings, and while free cash flow of $1.285B provides some support, a downturn in sales could force a dividend cut or further balance sheet deterioration. Additionally, revenue is heavily concentrated in skin care (49% of sales) and in the Asia-Pacific/travel retail channel (32% of revenue), making the company vulnerable to regional economic slowdowns or geopolitical disruptions.
Market and competitive risks are also material. The stock trades at a trailing P/E of 157.9x and EV/EBITDA of 40.4x, leaving no room for error; any disappointment could trigger a sharp multiple compression. With a beta of 1.274, EL is more volatile than the market, and it has underperformed the S&P 500 by 21.11 percentage points year-to-date. The prestige beauty market is highly competitive, with nimble indie brands and mass-market players encroaching on share. Recent news highlights the company's decision to walk away from merger talks with Puig, which removes a potential takeover premium but also eliminates a distraction; however, the independent turnaround plan must now deliver. Regulatory risks, such as changes in travel retail regulations or tariffs, could also impact margins.
The worst-case scenario would be a double-dip recession in China, a collapse in travel retail demand, and a failure to sustain margin improvements, leading to earnings falling short of the $4.25 forward EPS estimate. In that scenario, the stock could retest its 52-week low of $66.22, representing a 31.8% decline from the current price of $97.12. The analyst low target of $70.00 implies a 27.9% downside. Given the max drawdown of 43.79% over the past year, investors should be prepared for significant volatility. A more severe outcome, such as a dividend cut or a leverage crisis, could push the stock below $60, but that is not our base case.
FAQ
The key risks are: (1) Financial risk: high debt-to-equity of 2.43 and current ratio of 1.22, with interest expense consuming 23% of operating income. (2) Operational risk: revenue concentration in skin care (49%) and Asia-Pacific/travel retail (32%), making it vulnerable to regional downturns. (3) Valuation risk: trailing P/E of 157.9x and EV/EBITDA of 40.4x leave no margin for error; any earnings miss could trigger a sharp sell-off. (4) Competitive risk: intense competition from indie brands and mass-market players could erode market share and pricing power. (5) Macro risk: beta of 1.274 means the stock is more volatile than the market, and a global recession could hit discretionary beauty spending. The most severe risk is a failure of the turnaround, which could push the stock back to its 52-week low of $66.22.
Our 12-month forecast has three scenarios: Bull case (25% probability) with a target range of $120-127, assuming revenue growth accelerates to 6-8% and margins expand to 12-14%. Base case (55% probability) with a target range of $100-110, assuming revenue growth of 3-5% and EPS of $4.25. Bear case (20% probability) with a target range of $66-70, assuming a stall in the turnaround and revenue decline. The most likely scenario is the base case, which aligns with the analyst average target of $107.04. The key assumption is that the company continues to show modest revenue growth and margin improvement, without major macroeconomic shocks. If the company beats expectations, the bull case could play out; if it misses, the bear case is likely.
On trailing metrics, EL is significantly overvalued: the trailing P/E is 157.9x, EV/EBITDA is 40.4x, and P/B is 7.52x, all well above typical consumer defensive peers. However, on forward estimates, the valuation is more reasonable: the forward P/E is 24.82x based on EPS of $4.25, which is in line with the sector. The market is pricing in a successful turnaround, as evidenced by the 10.2% upside to the average analyst target. If the company fails to meet the $4.25 EPS estimate, the stock could be overvalued even on forward metrics. Relative to its own history, the forward P/E is below the trailing average, but the trailing metrics are distorted by depressed earnings. Overall, the stock appears fairly valued on forward estimates but overvalued on current fundamentals.
EL is a good buy only for investors who believe in the turnaround story and can tolerate volatility. The stock trades at $97.12, with a consensus target of $107.04 (10.2% upside) and a high target of $127 (30.8% upside). However, the downside risk is significant: the 52-week low is $66.22, implying 31.8% downside, and the trailing P/E of 157.9x leaves no room for error. The company has shown progress with 4.56% revenue growth and margin expansion, but the high debt-to-equity of 2.43 and low current ratio of 1.22 are concerns. For risk-averse investors, it may be better to wait for a pullback or more consistent earnings before buying. For those with a higher risk appetite, a small position could be justified as a speculative turnaround play.
EL is more suitable for a medium-to-long-term investment horizon (1-2 years) for investors who believe in the turnaround. The company is in a transition phase, and the full benefits of margin recovery and revenue acceleration may take several quarters to materialize. The high beta of 1.274 and max drawdown of 43.79% indicate significant volatility, making it less suitable for short-term trading unless one is adept at timing. The dividend yield of 1.78% provides some income, but the payout ratio of 279% on trailing EPS is unsustainable without earnings growth. A minimum holding period of 12-18 months is recommended to allow the turnaround to progress. Short-term traders could exploit volatility around earnings, but the risk/reward is less favorable.
